32 results about "Ige reactivity" patented technology

The disclosure provides the development of enantiomer-specific 7V-arylpyrazole dipeptides as novel N0D2 agonists which are effective at promoting immune checkpoint inhibitor therapy requiring N0D2 for activity. Given the significant functions of N0D2 in innate and adaptive immunity, these novel agonists afford new therapeutic compounds for a variety of NOD2-responsive diseases.

The present invention relates to a biomarker for predicting immunotherapeutic responsiveness based on spatial transcriptome analysis and uses thereof and, in particular, to: a marker composition for predicting the responsiveness of cancer patients to immunotherapy; a composition for predicting the responsiveness of cancer patients to immunotherapy; a kit for predicting the responsiveness of cancer patients to immunotherapy, comprising the composition; a method for providing information for predicting the responsiveness of cancer patients to immunotherapy; and a method for providing information for predicting the survival prognosis of cancer patients. The biomarker for predicting immunotherapeutic responsiveness, according to the present invention, was discovered by applying spatial transcriptome technology and analyzing cell group-specific gene expression values according to location information of cells in tissue sections, and can more precisely and accurately predict the responsiveness of cancer patients to immunotherapy and the survival prognosis of patients, thus enabling suitable treatments for patient groups, which may result in improved therapeutic effects and a reduction in pain and costs for patients.

Provided herein are compositions, systems, kits, and methods for detecting, in a DNA sample from a subject (e.g., overweight or obese subject), the presence of at least one polymorphism in the Neurobeachin (NBEA) gene. In particular embodiments, once at least one such polymorphism is detected, the subject is treated with, or provided with, a Glucagon-like peptide-1 receptor agonist (GLP-1RA).

The application belongs to the technical field of biological medicine, and particularly relates to application of a reagent for detecting anti-DLAT autoantibody in preparation of a product for detecting and / or diagnosing immune-mediated necrotizing myopathy. Experiments prove that DLAT can be used as a recognition antigen of an immune-mediated necrotizing myopathy related autoantibody, DLAT is a target point of the immune-mediated necrotizing myopathy autoantibody, the reactivity of the anti-DLAT autoantibody with the related antigen in dermatomyositis is 0%, the reactivity of the anti-DLAT autoantibody with other antigens HMGCR and SRP of the immune-mediated necrotizing myopathy is 0%, the anti-DLAT autoantibody is a new biological marker of the immune-mediated necrotizing myopathy, and the immune-mediated necrotizing myopathy can be detected and / or diagnosed.

The present disclosure provides oncolytic viruses expressing a modulator of interferon regulatory factors (IRFs), and compositions comprising thereof. The present disclosure further provides methods of using said oncolytic viruses and compositions for treating cancer, and for improving a subject's responsiveness to an immunomodulatory agent (e.g., an immune checkpoint inhibitor).

A cell-free DNA fragmentome method (DELFI-TF) is described to evaluate circulating tumor fraction during therapy. DELFI-TF rapidly determined disease progression in patients receiving immunotherapy.

The application discloses an anti-goat CD207 single-chain antibody and a preparation method and application thereof. Based on nucleotide sequences of heavy chain and light chain variable regions of obtained anti-goat CD207 monoclonal antibodies, a single-chain antibody capable of specifically combining with goat CD207 protein is obtained through single-chain antibody gene construction and prokaryotic expression, a heavy chain variable region amino acid sequence of the single-chain antibody is shown as SEQ.ID.NO.1, and a light chain variable region amino acid sequence is shown as SEQ.ID.NO.2. The anti-goat CD207 single-chain antibody of the application has good reactivity with goat CD207 protein.

The invention provides immunoconjugates of Formula I comprising an anti-HER2 antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The invention also provides 8-Het-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.

Compositions and methods are provided for isolating, manipulating and using for therapeutic and other purposes, mammalian, MHC Class I restricted, antigen-specific regulatory T cells. The regulatory T cells can be characterized as CD8+ cells that specifically suppress the responses of self-reactive and / or pathogenic CD4+ T cells by cytotoxic mechanisms including, without limitation, perforin, other components of the perforin / granzyme apoptosis pathway, etc. The regulatory T cells are antigen-specific, but are not activated by the same antigen as the self-reactive and / or pathogenic CD4+ T cells. In humans the regulatory T cells express inhibitory KIR proteins, e.g. one or more of KIR2DL2, KIR2DL3, and KIR3DL1.

Methods, systems, and kits for the diagnosis, prognosis and the determination of cancer progression of prostate cancer in a subject are disclosed. In particular, the disclosure relates to the use of immune cell-specific gene expression in determining prognosis and identifying individuals in need of treatment for prostate cancer who will be responsive to radiation therapy.

Non-responsiveness assessment in IBD patients The present invention relates to an in vitro method for predicting the response of patients with inflammatory bowel disease (IBD) to treatment with intracellular immunosuppressants. In this method, samples are collected from IBD patients in the early stages of treatment with an immunosuppressant of interest, and these samples contain effector mononuclear cells. Responsiveness is predicted based on the difference between the activity level of the multidrug-resistant ABC transporter and the activity level of the reference transporter in effector mononuclear cells in the sample. This method is useful in the treatment of IBD and can be used, for example, to monitor disease progression or to determine whether to switch from the initial treatment to another medication (e.g., csDMARD or tsDMARD).

We provide a vaccine against 2019-nCoV infection. [Solution] A fusion protein is provided comprising a spike protein derived from 2019-nCoV having at least 90% identity with a specific sequence; or a fragment thereof having common antigen cross-reactivity with the spike protein, wherein the fragment may preferably include, or consist of, a receptor-binding domain (RBD) of the 2019-nCoV spike protein having at least 90% identity with a specific sequence.

This application relates to site-specific conjugation of antibody lysine residues using solid phase immobilized microbial transglutaminase MTG and MTG in solution. Site-specific modification of proteins using microbial transglutaminase (MTG) is a powerful and versatile strategy for controlled modification of proteins under physiological conditions. We present evidence that solid phase microbead immobilization can be used to site-specifically and efficiently link different functional molecules important for further downstream applications to therapeutically relevant proteins, including scFV, Fab fragments and antibodies. We demonstrate that MTG remains firmly immobilized and there is no detectable column bleed and the enzyme activity is maintained during continuous operation, which allows for convenient recycling of the enzyme, thus outperforming solution phase MTG conjugation. Furthermore, it is shown that immobilized MTG exhibits an enhanced selectivity for certain residues in the presence of several reactive residues, all of which are targeted if conjugation is performed in solution. Site-specific lysine conjugation of antibodies using immobilized and solution MTG with a highly efficient glutamine-containing peptide is also reported. In addition, the generation of bis-site-specific conjugated IgGl with site-specific conjugation of both glutamine and lysine residues of an IgGl antibody using immobilized and solution MTG is reported. Site-specific glutamine conjugation with small peptides containing lysine residues and functional moieties is also described.

The present invention relates to a biomarker for predicting therapeutic response in asthma patients and a use thereof, and specifically, to a method for predicting therapeutic response to an anti-interleukin 4 receptor antibody (anti-IL-4R antibody), an anti-interleukin 5 antibody (anti-IL-5 antibody), or an anti-interleukin 5 receptor antibody (anti-IL-5R antibody), which is being used as a therapeutic agent for asthma, by using eicosanoids, and the like.

The present application relates to the technical field of immunological detection, in particular to hepatitis B PreS1 antigen and its preparation method and application. The present application first selects an active PreS1 polypeptide sequence, which is coupled to a hepatitis B surface antigen HBsAg molecule through a crosslinking agent to obtain a hepatitis B PreS1 antigen having both hepatitis B surface antigen activity and PreS1 antigen activity, which can be used as a calibrator and positive control in a hepatitis B PreS1 antigen detection kit. The kit uses anti-PreS1 antibody as coating and anti-HBsAg antibody as enzyme label. The artificial coupled hepatitis B PreS1 antigen prepared by the present application can effectively replace the currently used PreS1 real positive sample on the market, has no biological safety risk, stable source, and various indexes such as reactivity, vehicle stability and thermal stability, which are all better than those of the real positive sample, and has high innovation and applicability.

Production was attempted for antibodies that neutralize the activity of a bispecific antibody having F.VIII function-substituting activity, for use in a method for measuring the reactivity of F.VIII in the presence of a bispecific antibody having F.VIII function-substituting activity. As a result, it was discovered that by using the produced antibodies, F.VIII activity in the plasma of a hemophilia A patient can be evaluated accurately by performing APTT-based one-stage clotting assay on a wide range of bispecific antibodies having F.VIII function-substituting activity. It was also discovered that F.VIII inhibitor titer in the plasma of a hemophilia A patient carrying F.VIII inhibitor can be evaluated accurately by APTT-based Bethesda assay.

The application relates to a cat infectious peritonitis virus S protein receptor binding region monoclonal antibody and application thereof, relates to the technical field of biology, and aims to provide a cat infectious peritonitis virus S protein receptor binding region monoclonal antibody and application thereof.The amino acid sequence of a heavy chain variable region of the monoclonal antibody is shown in a sequence table SEQ ID NO.1, and the amino acid sequence of a light chain variable region is shown in a sequence table SEQ ID NO.2.The application adopts Western blot and IFA methods to identify the reactivity of MAb, and identifies an antigen epitope recognized by MAb.The antigen epitope is conservative in type I cat coronavirus, which indicates that the monoclonal antibody can recognize various type I FCoV strains, has broad spectrum, and is not accidentally directed to a single strain.The antigen epitope has no cross reaction with type II, which indicates that the specificity is high, can be used for distinguishing type I and type II infections, and has diagnostic application value.

The disclosure relates to compositions and methods for identifying reactive cysteines on nuclear proteins from cell samples. Further wherein the method includes contacting live cells, dead cells, cell lysates, nuclei, or a nuclear fraction obtained from cells with an electrophilic probe, and performing mass spectrometry analysis of proteins present in the cytoplasmic fraction.

The invention provides single domain heavy chain variable antibodies that specifically bind CD169. The invention further relates to methods of modulating an immune response in an individual using the single heavy chain variable domain antibody according to the invention, to an immunoreactive molecule and a pharmaceutical composition, comprising the single heavy chain variable domain antibody according to the invention.

The invention belongs to the technical field of veterinary biotechnology detection, and particularly relates to a monoclonal antibody for resisting duck adenovirus 3 type Fiber2 protein and application of the monoclonal antibody to detection or identification of duck adenovirus 3 type. The duck adenovirus 3 type Fiber2 protein is taken as an immunogen to screen a hybridoma cell strain with good reactivity to different strain whole viruses of the duck adenovirus 3 type, an antibody generated by the hybridoma cell strain is analyzed, the monoclonal antibody resisting the duck adenovirus 3 type Fiber2 protein is obtained, and the sequence information is shown in a table 3 in the specification. The monoclonal antibody provided by the invention can identify different strains of the duck adenovirus 3, does not generate cross reaction with other common poultry disease viruses such as fowl adenovirus, novel duck reovirus and the like, has good specificity and sensitivity, can be used for detecting the exogenous virus of the duck adenovirus 3 in poultry virus live vaccines, and has good application prospects. And the kit can also be used for clinical identification, virus content determination and epidemiological investigation of the duck adenovirus type 3.

The present invention provides: a lipid particle which exhibits excellent effects in terms of drug efficacy manifestation, safety (low toxicity), and the like; and a production method therefor. A lipid particle provided by the present invention is, for example, a lipid particle conjugated with an antibody that specifically binds to a cell surface antigen, or an antigen-binding fragment thereof, wherein: the antibody or antigen-binding fragment thereof is covalently bonded to at least a portion of a lipid (reactive polyethylene glycol (PEG) lipid) having a reactive PEG chain contained in lipid components constituting the lipid particle; and the ratio of the reactive PEG lipid, which is not covalently bonded to the antibody or antigen-binding fragment thereof, with respect to all of the lipid components constituting the lipid particle is at most 0.1 mol%.

The present invention relates to a pharmaceutical composition for the treatment and / or prevention of cancer, comprising as active ingredient an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein or a fragment of said protein comprising 7 or more contiguous amino acids.

An improved chemical probe for the detection of the amino acid citrulline combines: 1) a reactive head formed of 1,3-dicarbonyl moiety that reacts with a citrulline side chain in an improved manner compared to currently used 1,2-dicarbonyl moieties; and 2) a modular action of the probe where citrulline side chains are labeled first using reactive heads described above, and attachment of a read-out subunit or tag, be it a fluorophore, a nanoparticle, or an antigen is performed separately. The modular nature of the chemical probe increases the sensitivity of the probes due to their smaller size. Additionally, the chemical probes of the present disclosure allow the same sample to be analyzed using a variety of read-out methods.

The application provides an antigen epitope polypeptide and a paralichthys dentatus BMP2 protein specific antibody prepared by the antigen epitope, designs an antigen epitope through bioinformatics analysis, adopts a segmented recombination expression strategy to obtain BMP2-N and BMP2-C recombination proteins in view of the low expression efficiency of full-length BMP2 protein in a prokaryotic system, and uses the recombination proteins as immunogens to prepare polyclonal antibodies. It is verified through immunoblotting and immunofluorescence that the prepared antibodies can specifically recognize the paralichthys dentatus BMP2 protein, have high affinity and good reaction activity, and effectively avoid the problems of false negative or low signal caused by insufficient cross reactivity of the antibodies. On this basis, a BMP2 immunological detection kit is constructed, precise positioning and expression analysis of the BMP2 protein in mucous membrane tissues such as skin, gill and intestinal tract of the paralichthys dentatus can be realized. The antibody and the kit provide a reliable tool for studying the role of BMP2 in fish mucosal immunity, and have important scientific research value and application prospect.

The present application provides an immune inducer comprising a polynucleotide-peptide conjugate or a pharmaceutically acceptable salt thereof as an effective ingredient, the polynucleotide-peptide conjugate consisting of a single-stranded polynucleotide or polynucleotide derivative containing a CpG motif, a peptide, and a spacer covalently bonded at one end to the polynucleotide or polynucleotide derivative and covalently bonded at the other end to the peptide, the peptide being a peptide in which one or more consecutive amino acids at the N-terminus of an MHC-binding peptide are replaced with an amino acid having a reactive functional group for forming a covalent bond with the spacer, wherein the one or more consecutive amino acids do not include anchor residues for binding to MHC.

Provided herein is a recombinant cell comprising a deletion of a gene encoding a transporter associated with antigen processing (TAP) protein and mutations in the CD3 epsilon gene and an HLA-A gene. Also provided are systems and methods for screening for alloreactivity and specificity of an immunotherapeutic agent, such as a bispecific T cell engager or an engineered T cell receptor (TCR).